Posterior chamber phakic intraocular lenses after penetrating keratoplasty

Abstract

Results indicate that phakic intraocular lens implantation is a viable treatment for myopia and astigmatism after PKP in patients for whom glasses, contact lenses, or corneal refractive surgery are contraindicated.

New clinical pathways for keratoconus

“…A number of recent papers have reported effective refractive correction using pIOLs in keratoconus (post-operative spherical equivalent range À 0.08 ± 0.4 to þ 0.1 ± 0.4; 64-67% within 0.5D and 84-100% within 1D of target refraction) [61][62][63][64][65][66] and for post-keratoplasty ametropia. 67 Of the pIOLs available, 68 the Visian ICL (Staar Surgical, Monrovia, CA, USA) offers the longest safety track record for an injectable pIOL and is available in a wide range of powers (including toric correction up to 6D). Pesando et al 69 reported retrospective 10-year follow-up data in 59 ICLimplanted hypermetropic eyes, showing a mean endothelial cell loss of 4.7%, mostly occurring within the first few weeks of implantation and remaining almost unchanged thereafter.…”

The posterior chamber phakic refractive lens (PRL): a review

“…16 There are a number of studies evaluating the outcomes obtained with the different models of ICL, and therefore there is a complete characterization of the refractive outcomes and complications resulting from the implantation of this pIOL. [17][18][19][20][21][22][23][24] The current review will focus on the other available posterior chamber pIOL, the PRL, which has been very recently removed from the market. This pIOL was initially developed in 1987, now in its third generation, and was conceived to be implanted in the posterior chamber through an autosealing corneal incision.…”

Three-year follow-up of subjective vault following myopic implantable collamer lens implantation

“…Clinical results of phakic posterior chamber intraocular lenses (IOLs) have confirmed this procedure as a promising treatment option for patients who cannot be subjected to keratorefractive procedures, the main advantages of phakic IOLs being the correction of higher levels of myopia and This research was supported in part by Research Grants (Ministerio de Ciencia e Innovación, SAF2008-01114-E and SAF2009-13342) to Robert Montés-Micó and a Fundação para a Ciência e Tecnologia hyperopia and the reversibility of the procedure [1][2][3][4][5][6][7]. Presently, one of the most widely used phakic posterior chamber IOLs is the ICLV4, known as Implantable Collamer Lens (ICL), manufactured by STAAR Surgical (STAAR Surgical, Monrovia, CA, USA).…”